- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04017052
Application of a TBE-Vaccine in Obese Persons
Obese people have an altered immune responsiveness. The present study investigates whether this influences immune responses to booster vaccinations (i. e. booster vaccination with TBE vaccine "FSME Immun") and if a modification of vaccination schedules is needed.
Obese adults (BMI >30) >18 - 60 years are compared with adults with normal weight (BMI <25) concerning TBE-NT- antibody titers, TBE- NT antibody titer course and cellular immunity. Metabolic parameters and sexual hormones will be tested and compared as well.
Study Overview
Detailed Description
Obese people have an altered immune responsiveness. Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infection.We investigate whether this influences immune responses to booster vaccinations (i. e. booster vaccination with TBE vaccine "FSME Immun") and if a modification of vaccination schedules is needed.
The investigators will test and compare the humoral and cellular immune response of obese persons (BMI>30) and persons with normal weight (BMI<25) before and after a booster with FSME Immun.
The aim of the study is to clarify if a modification of vaccination schedules or a change of booster intervals is necessary for obese people. Furthermore this study will increase our understanding of the influence of obesity on different components of the immune system, as well as on the quality and quantity of the immune responses.
At Screening (visit 1) demographic parameters (age, gender, weight, BMI, waist/hip-ratio) will be recorded and metabolic parameters (Cholesterol, Triglycerides, HDL, LDL, Apolipoproteine, Lp(a), Glucose, Fructosamin, Leptin, Leptinreceptor on T- and B-cells (PCR), Insulin, high-sensitive CRP) and sex hormones (Testosterone, Estrogen, Progesteron, FSH, LH) will be tested. At visit 3 some metabolic parameters (Cholesterol, Triglycerides, HDL, Glucose, Fructosamin, Insulin und high-sensitive CRP) will be tested again. All parameters will be compared and correlated with humoral and cellular immune responses.
Immunglobulins: IgG, IgE, IgD, IgM, IgA will be tested at visit 1-4.
TBE antibody titers (NT) will be tested and titer course will be evaluated at visit 1-5.
At visit 1 und 2, isolation of PBMC (Peripheral Blood Mononuclear Cells) with Ficoll gradient will be carried out and the following tests will be performed:
- Cytokine concentrations will be measured after re-stimulating the PBMC with TBE-Antigen. Duration of stimulaton: 48h; Detection with Luminex platform/ELISA: IL-2, IFNgamma, IL-10, TNF-alpha und IL-6
- Flow cytometry: Characterization of different lymphocyte-subpopulations with antibody-panels (CD surface markers: CD19, CD3, IgD, IgM, IgG, IgA, CD10, CD27, CD127, CCR4, CD8, CD4, CD28, CD31, CD38, CCR7, CD45RA, CD25, CD24, CD38 und FOXP3).
Serious adverse events and adverse events will be recorded at all visits
All participants will be tested again at V5, performing TBE-Neutralisation-Test three years after the booster vaccination for analysis of longterm immunogenicity. Demographic parameters will be recorded again.
Participants who are not protected against TBE for another year, three years after the booster vaccination at V5 (NT <20), will receive a booster vaccination for free.
V1 day 0, V2 day 7+3,V3 1 month +/-7 days, V4 6 months +/-14d V5 36 months+/- 1 month V6 only if TBE NT<20
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
main Inclusion Criteria:
- willingness to sign written informed consent form
- completed primary TBE immunization and at least 1 booster vaccination
- participants of both sexes between 18 and 60 years of age
main Exclusion Criteria:
- age < 18 and > 60 years
- BMI 25-30
- previous TBE infection
- pregnancy or breast feeding
- acute infection on day of inclusion (day 0) or at visit 5 (36 months), body temperature > 37,9°C
- concomitant medications: systemic cortison therapy, chemotherapy, immunotherapy (allergy) immunsuppressive therapy 4 weeks prior or during the study
- administration of other vaccines 4 weeks before/after day 0
- planned surgery within 2 weeks before/after TBE booster
- any contraindication to administration of FSME-Immun® vaccine according to manufacturer's instructions
- malignant diseases within 5 years prior to the study
- autoimmune diseases
- kidney insufficiency, dialysis
- drug addiction
- plasma donor
- receipt of blood transfusions or immunoglobulins within 3 months prior to study entry / within 3 months prior to visit 5
- Severe disease with hospitalization or surgery 3 months before or during the study
- participation in a clinical trial simultaneously to visit 1-4 with receipt of vaccination and/or investigational product within one month before booster
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Booster vaccination
Intervention = one i.
m.
TBE booster vaccination (FSME-Immun) at visit 1.
|
Booster with TBE vaccine (i.m.) FSME Immun
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral immunity (TBE NT)
Time Frame: 1 month +/- 7 days after booster (v3)
|
Humoral immunity tested with TBE Neutralisation test- Neutralizing antibody titer against TBE
|
1 month +/- 7 days after booster (v3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TBE-NT titer course
Time Frame: before booster at day 0 at all visits until 3 years after booster vaccination at V5 (36 months+/-1 month)
|
TBE-NT titer course evaluation
|
before booster at day 0 at all visits until 3 years after booster vaccination at V5 (36 months+/-1 month)
|
Cellular immune response with flow cytometry
Time Frame: evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)
|
Cellular immune response: Characterisation of lymphocyte sub-population with flow cytometry: detection of CD surface markers of lymphocytes with antibody panels - CD19, CD3, IgD, IgM, IgG, IgA, CD10, CD27, CD127, CCR4, CD8, CD4, CD28, CD31, CD38, CCR7, CD45RA, CD25, CD24, CD38 und FOXP3 |
evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)
|
Measurement of Cytokines with Luminex platform/ELISA
Time Frame: evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)
|
Measurement of cytokines IL-2, IFNgamma, IL-10, TNF-alpha und IL-6 in supernatants of PBMC cultures re-stimulated with TBE antigen; duration of stimulation: 48h. Measurement with Luminex Platform/ELISA |
evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ursula Wiedermann-Schmidt, MD, PhD, Medical University of Vienna , ISPTM
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Tick-Borne Diseases
- Encephalitis
- Encephalitis, Tick-Borne
Other Study ID Numbers
- TBE_obesity_1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tick Borne Encephalitis
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)TerminatedTick-Borne Disease | Encephalitis, Tick-Borne | Tick-Borne Encephalitis | Glycoprotein E, Flavivirus | NSI Protein, FlavivirusUnited States
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedTick Borne EncephalitisAustria
-
PfizerCompletedTick-borne Encephalitis (TBE)Poland
-
Sykehuset TelemarkNorwegian Institute of Public Health; Oslo University Hospital; Sorlandet Hospital... and other collaboratorsRecruiting
-
PfizerCompleted
-
GlaxoSmithKlineNovartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompletedTick-Borne EncephalitisUnited States
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
University of SurreyCompletedTick-Borne EncephalitisUnited Kingdom
Clinical Trials on FSME-IMMUN Vaccine
-
Region Örebro CountyNot yet recruiting
-
Elisabethinen HospitalBaxter Healthcare Corporation; ASOKLIFUnknownTick Borne EncephalitisAustria, Czech Republic
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedTick Borne EncephalitisAustria
-
PfizerCompletedTick-borne EncephalitisAustria, Germany, Poland
-
PfizerCompleted
-
PfizerCompletedEncephalitis, Tick-BornePoland
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)TerminatedTick-Borne Disease | Encephalitis, Tick-Borne | Tick-Borne Encephalitis | Glycoprotein E, Flavivirus | NSI Protein, FlavivirusUnited States
-
PfizerCompletedTick-borne Encephalitis (TBE)Poland
-
PfizerCompletedEncephalitis, Tick-BorneAustria, Germany, Poland
-
University of ZurichDivision of Infectious Diseases and Hospital EpidemiologyCompleted